Related by context. All words. (Click for frequent words.) 76 hormone refractory prostate cancer 72 metastatic colorectal cancer 72 mRCC 71 HER2 positive metastatic breast 71 metastatic renal cell carcinoma 71 NSCLC 69 carboplatin paclitaxel 69 axitinib 69 metastatic CRC 69 prostate cancer CRPC 69 castration resistant prostate cancer 68 advanced NSCLC 68 HER2 positive breast cancer 68 Bezielle 67 B CLL 67 glufosfamide 67 elacytarabine 67 metastatic renal cell 67 relapsed multiple myeloma 67 relapsed ovarian cancer 67 oral ridaforolimus 67 adecatumumab 67 Amrubicin 67 metastatic hormone refractory 67 heavily pretreated 67 Metastatic Colorectal Cancer 67 resistant ovarian cancer 67 Aflibercept 67 multiple myeloma MM 66 phase IIb clinical 66 EGFR expressing 66 mapatumumab 66 refractory multiple myeloma 66 pomalidomide 66 castrate resistant prostate cancer 66 metastatic CRPC 66 temsirolimus 66 Fludara 66 sorafenib tablets 66 FOLFIRI 65 Targretin 65 metastatic castration resistant 65 YONDELIS 65 imatinib therapy 65 superficial bladder cancer 65 forodesine 65 sorafenib Nexavar 65 PXD# 65 assessing T DM1 65 SCCHN 65 docetaxel 65 Cloretazine 65 vinorelbine 65 platinum refractory 65 docetaxel Taxotere ® 65 metastatic RCC 65 Torisel 65 estramustine 65 aflibercept 65 prostate cancer HRPC 65 Phase #/#a trial 65 ganetespib 65 recurrent ovarian cancer 65 indolent NHL 65 metastatic colorectal 65 Proxinium TM 64 Troxatyl 64 ELACYT 64 registrational trial 64 nab paclitaxel 64 metastatic castrate resistant 64 androgen independent 64 alvespimycin 64 AQ4N 64 Ozarelix 64 Taxotere ® 64 CA4P 64 bevacizumab Avastin ® 64 recurrent NSCLC 64 plus prednisone 64 SNT MC# 64 seliciclib 64 ixabepilone 64 chronic lymphocytic leukemia CLL 64 HGS ETR1 64 PEG SN# 64 mCRC patients 64 HER2 positive 64 mCRC 64 Irinotecan 64 vandetanib 64 T DM1 64 recurrent glioblastoma multiforme 64 INCB# [001] 64 Advanced Renal Cell 64 OncoVEX GM CSF 64 pancreatic carcinoma 64 metastatic HRPC 64 Panzem R NCD 64 cetuximab Erbitux 64 dacarbazine 64 relapsed MM 64 decitabine 64 dasatinib 64 custirsen 64 anti leukemic 64 FOLOTYN 64 pancreatic adenocarcinoma 64 heavily pretreated patients 64 Fludara ® 64 sapacitabine 64 Erlotinib 64 hematological malignancies 64 lymphoma CTCL 63 Genasense ® 63 Aplidin 63 leukemia CLL 63 evaluating T DM1 63 gastrointestinal stromal tumors 63 TREANDA 63 metastatic breast cancer 63 Herceptin trastuzumab 63 advanced carcinoid 63 recurrent GBM 63 bone metastasis 63 cabazitaxel 63 Virulizin ® 63 Fibrillex TM 63 cytotoxic therapy 63 cell lymphoma CTCL 63 stage IIIB 63 lenalidomide Revlimid R 63 lumiliximab 63 obatoclax 63 chemoradiotherapy 63 prostate cancer AIPC 63 Cloretazine ® 63 paclitaxel carboplatin 63 HGS ETR2 63 CYT# potent vascular disrupting 63 sunitinib malate 63 HER2 negative 63 CTAP# Capsules 63 Golimumab 63 gefitinib 63 refractory metastatic colorectal cancer 63 IMA# 63 tesmilifene 63 leukemia AML 63 EGFR expressing mCRC 63 EndoTAGTM 1 63 Xcytrin 63 trastuzumab Herceptin R 63 TORISEL 63 nonmetastatic 63 gemcitabine carboplatin 63 galiximab 63 monotherapy 63 gastrointestinal stromal tumor GIST 63 resminostat 63 Taxotere R 63 receptor tyrosine kinase inhibitor 63 pertuzumab 63 Cloretazine R 63 trastuzumab DM1 63 Nexavar sorafenib 63 MAGE A3 ASCI 63 epithelial tumors 63 CR# vcMMAE 63 thalidomide Thalomid 63 Cloretazine R VNP#M 62 pralatrexate 62 Hormone Refractory Prostate Cancer 62 valopicitabine 62 xenograft models 62 trastuzumab 62 cutaneous T cell 62 lintuzumab 62 EGFR TKI 62 sunitinib 62 Allovectin 7 R 62 perifosine 62 antibody MAb 62 depsipeptide 62 erlotinib Tarceva ® 62 relapsed refractory 62 docetaxel chemotherapy 62 pegylated liposomal doxorubicin 62 Pemetrexed 62 chlorambucil 62 MOZOBIL 62 metastatic GIST 62 trabectedin 62 stage IIIb IV 62 alkylating agent 62 Telintra 62 pemetrexed 62 TEMODAL 62 ofatumumab 62 Perifosine 62 Hepatocellular Carcinoma HCC 62 ZACTIMA 62 metastatic malignant melanoma 62 azacitidine 62 dasatinib Sprycel ® 62 enzastaurin 62 Vicinium TM 62 IL# PE#QQR 62 sipuleucel T 62 EndoTAG TM -1 62 bendamustine 62 SPRYCEL ® 62 voreloxin 62 MGCD# [001] 62 fallopian tube carcinoma 62 Voreloxin 62 renal cell carcinoma 62 Xanafide 62 nilotinib 62 Ceflatonin 62 malignant pleural mesothelioma 62 previously untreated follicular 62 standard chemotherapy regimen 62 refractory metastatic 62 Dacogen injection 62 IMC A# 62 Traficet EN 62 lintuzumab SGN 62 metastatic gastric 62 Trastuzumab 62 Blinatumomab 62 zalutumumab 62 metastatic sarcomas 62 relapsed refractory multiple myeloma 62 Lenocta 62 imatinib Gleevec ® 62 unresectable locally advanced 62 gemcitabine 62 gefitinib Iressa 62 VNP#M 62 hepatocellular cancer 62 Tarceva erlotinib 62 bone metastases 62 Renal Cell Carcinoma RCC 62 HuMax CD4 62 AEG# 62 EFAPROXYN 62 IRX 2 62 oblimersen 62 refractory CTCL 62 R sorafenib tablets 62 Glufosfamide 62 Abiraterone acetate 62 metastatic melanoma 61 cediranib 61 Personalized Immunotherapy 61 vismodegib 61 Cutaneous T 61 haematological malignancies 61 refractory CLL 61 PSMA ADC 61 vidofludimus 61 Romidepsin 61 Doxil ® 61 TELCYTA 61 Tavocept 61 Ixempra 61 bevacizumab Avastin 61 secondary hyperparathyroidism 61 abiraterone acetate 61 pan HDAC inhibitor 61 Pazopanib 61 IMGN# 61 Tamibarotene 61 KRN# 61 adjuvant radiation 61 CLL SLL 61 Omacetaxine 61 elotuzumab 61 Urocidin 61 systemic ALCL 61 Velcade bortezomib 61 GvHD 61 eosinophilic asthma 61 AVASTIN 61 advanced metastatic prostate 61 evaluating tivozanib 61 XGEVA 61 cytotoxic chemotherapy 61 low dose cytarabine 61 cetuximab Erbitux ® 61 Pivotal Phase III 61 HGS# 61 Nexavar ® 61 pegfilgrastim 61 alfa 2a 61 Annamycin 61 OMP #M# 61 Phase 2a trial 61 DLBCL 61 nucleoside analog 61 PKC# 61 ovarian carcinoma 61 Imprime PGG 61 TRISENOX 61 brain metastases 61 panitumumab Vectibix 61 CIMZIA TM 61 invasive bladder 61 neoadjuvant therapy 61 pegylated interferon alpha 61 non squamous NSCLC 61 Tarceva TM 61 amrubicin 61 adjuvant therapy 61 relapsed AML 61 tivozanib 61 KRAS mutations occur 61 advanced unresectable 61 Rituximab 61 Phase 2b study 61 MDS AML 61 goserelin 61 mycophenolate mofetil 61 MGd 61 AP# [003] 61 Brentuximab Vedotin SGN 61 Gefitinib 61 metaglidasen 61 MabThera Rituxan 61 histone deacetylase HDAC inhibitor 61 dasatinib Sprycel 61 LHRH receptor positive 61 Vectibix 61 Bevacizumab 61 atacicept 61 ularitide 61 pharmacokinetic PK study 61 registrational 61 Sutent sunitinib 61 cancer mCRC 61 Randomized Phase 61 BRAF inhibitor 61 PNP inhibitor 61 budesonide foam 61 vinca alkaloid 61 anthracycline taxane 61 Azedra 61 thymalfasin 61 refractory acute myeloid 61 EGFr 61 oral deforolimus 61 lupus nephritis 61 deforolimus 61 KRAS status 61 hematologic malignancies 61 tesetaxel 61 neoadjuvant treatment 61 Neoadjuvant 61 FOLFOX6 61 EGFR tyrosine kinase inhibitors 61 lymphoid malignancies 61 antithrombotic 61 TroVax ® 61 sunitinib Sutent 61 radiation sensitizer 61 refractory APL 61 CYC# 61 recurrent glioblastoma 61 novel histone deacetylase 61 differentiated thyroid 61 irinotecan chemotherapy 61 CIMZIA ™ 61 Phase Ib clinical trials 61 Metastatic Prostate Cancer 61 omacetaxine mepesuccinate 61 Hodgkin lymphoma HL 61 dacetuzumab 61 gemcitabine chemotherapy 61 trastuzumab Herceptin ® 61 relapsed SCLC 61 APTIVUS r 61 docetaxel Taxotere R 60 HER2 overexpression 60 TELINTRA 60 unresectable 60 octreotide implant 60 SERMs 60 BAY #-# 60 Gemcitabine 60 advanced metastatic renal 60 ZOLINZA 60 KRAS wild 60 baminercept 60 SUCCEED trial 60 DMARD 60 adalimumab Humira 60 IRESSA 60 immunomodulatory therapy 60 medullary thyroid cancer 60 HSP# inhibitor 60 CCR5 antagonist 60 olaparib 60 antitumor activity 60 hepatitis C HCV 60 EGFR inhibitors 60 SUTENT 60 castrate resistant 60 hepatocellular carcinoma HCC 60 Erbitux cetuximab 60 Phase III randomized controlled 60 chronic angina 60 ozarelix 60 targeting CD# 60 Vandetanib 60 Phase 2b Clinical Trial 60 topotecan 60 refractory PTCL 60 chemotherapeutic regimen 60 relapsing remitting MS RRMS 60 melphalan prednisone 60 huC# DM4 60 tamibarotene 60 aflibercept VEGF Trap 60 Raptiva ® 60 anti TNF 60 interferon gamma 1b 60 symptomatic BPH 60 multi kinase inhibitor 60 FOLFOX4 60 hormone refractory 60 refractory colorectal cancer 60 proteasome inhibitor 60 EOquin 60 HuMax EGFr 60 CD# antibody [001] 60 Diffuse Large B 60 phase IIa clinical 60 OHR/AVR# 60 BCIRG 60 LEUKINE 60 Amigal 60 zanolimumab 60 Alocrest 60 dirucotide 60 luteinizing hormone releasing 60 metastatic kidney 60 VEGF receptor inhibitor 60 PDX pralatrexate 60 refractory chronic lymphocytic 60 biologic therapy 60 Gemzar ® 60 Phase Ib study 60 Octreolin 60 GW# [003] 60 anti TNF alpha 60 velafermin 60 MYDICAR ® 60 generation Hsp# inhibitor 60 ACTEMRA TM 60 Fludarabine 60 iniparib 60 riociguat 60 tumors GIST 60 Luteinizing Hormone Releasing Hormone 60 bosutinib 60 taxane chemotherapy 60 paclitaxel Taxol 60 temozolomide 60 Rituxan rituximab 60 Pirfenidone 60 hematological cancers 60 elagolix 60 Phase Ib II 60 unresectable stage 60 Relapsed Refractory 60 CHOP chemotherapy 60 pain palliation 60 multiple myeloma 60 clodronate 60 Clolar ® 60 Neulasta ® 60 Archexin 60 FUSILEV enhances 60 Dasatinib 60 tyrosine kinase inhibitors 60 fluoropyrimidine 60 refractory AML 60 imatinib Gleevec 60 panobinostat 60 Sudhir Agrawal D.Phil 60 Vidaza azacitidine 60 Triapine R 60 advanced hepatocellular carcinoma 60 ibandronate 60 demonstrated antitumor activity 60 Taxotere chemotherapy 60 metastatic pancreatic 60 HDAC Inhibitor 60 ALN TTR# 60 cetuximab Erbitux R 60 anthracyclines taxanes 60 gemcitabine Gemzar 60 Cytoxan 60 Gleevec Glivec 60 dose cohorts 60 lorvotuzumab mertansine 60 relapsed refractory AML 60 remission induction 60 Avastin bevacizumab 60 Phase III Clinical Trial 60 evaluating picoplatin 60 crizotinib PF # 60 Atypical Hemolytic Uremic Syndrome 60 Seliciclib 60 dosing cohort 60 ritonavir boosted 60 ErbB2 positive 60 imetelstat 60 posaconazole 60 vascular disrupting agents 60 Exherin TM 60 Folotyn 60 Revlimid lenalidomide 60 IV melanoma 60 Epidermal Growth Factor Receptor 60 Xelox 60 phase IIb trial 60 pegylated liposomal doxorubicin PLD 60 mTOR inhibitor 60 OMP #R# 60 TACE 60 veltuzumab 60 ospemifene 60 neoadjuvant chemotherapy 59 noninfectious uveitis 59 dose cohort 59 OPAXIO 59 non metastatic osteosarcoma 59 follicular NHL 59 entinostat 59 cMET 59 OXi# 59 Allovectin 7 ® 59 SAR# [004] 59 randomized Phase IIb 59 Castration Resistant Prostate Cancer 59 TYKERB 59 Apoptone 59 Peginterferon alfa 2b 59 HCV RESPOND 2 59 biliary tract cancer 59 recurrent glioma 59 anticancer therapy 59 aromatase inhibitors AIs 59 Pertuzumab 59 talactoferrin 59 BCG refractory 59 CD3 monoclonal antibody 59 anti EGFR antibody 59 neoadjuvant 59 TKI therapy 59 CEQ# 59 paclitaxel Taxol ® 59 OMAPRO 59 investigational therapies 59 TTF Therapy 59 CCX# 59 ribavirin therapy 59 ON #.Na 59 Virulizin R 59 PEGylated interferon beta 1a 59 recurrent metastatic 59 XYOTAX TM 59 FOLFOX 59 5 fluorouracil leucovorin 59 Multiple Myeloma MM 59 belinostat 59 mTOR inhibitors 59 cilengitide 59 Carfilzomib 59 fosbretabulin 59 refractory ovarian cancer 59 EGFR mutation positive 59 romidepsin 59 sorafenib 59 #mg/m# [001] 59 medically inoperable 59 leukemia ALL 59 hormone refractory metastatic prostate 59 novel anticancer 59 EGFR mutations 59 Acute Myeloid Leukemia AML 59 regorafenib 59 investigational monoclonal antibody 59 R lenalidomide 59 haematologic malignancies 59 Ophena TM 59 operable breast cancer 59 LHRH agonists 59 Faslodex 59 erlotinib 59 cinacalcet HCl 59 TBC# 59 FOLPI 59 Phase #b/#a trial 59 EGFR mutation 59 lesinurad 59 grade cervical intraepithelial 59 Epratuzumab 59 Cotara 59 Atiprimod 59 CoFactor 59 Surgical resection 59 adriamycin 59 HER2 + 59 atrial fibrillation budiodarone ATI 59 sorafenib Nexavar ® 59 FOLOTYN ® 59 mertansine 59 Meets Primary Endpoint 59 hepatocellular carcinoma 59 5 FU leucovorin 59 oral prodrug 59 metastatic colorectal carcinoma 59 rALLy 59 refractory prostate cancer 59 methylnaltrexone 59 refractory NSCLC 59 rindopepimut 59 Myelodysplastic Syndrome MDS 59 myelodysplastic syndromes MDS 59 metastatic disease 59 Phase IIIb clinical 59 panitumumab 59 PANVAC VF 59 Nicole Onetto MD 59 interferon ribavirin 59 daunorubicin 59 PRT# 59 Entereg R 59 Acute Myeloid Leukemia 59 HCV SPRINT 59 clinically localized prostate 59 VELCADE melphalan 59 Phase IIa trial 59 Panzem 59 PREZISTA r 59 advanced HER2 positive 59 Akt inhibitor 59 immunotherapeutic agent 59 Quinamed 59 flutamide 59 esophageal candidiasis 59 ATL# [001] 59 Bortezomib 59 Ceflatonin R 59 anthracycline containing 59 refractory indolent non 59 blinatumomab 59 cytoreduction 59 Insegia 59 relapsed leukemia 59 Factor VIIa 59 PD LID 59 chronic myeloid leukemia CML 59 Pegylated Interferon 59 tocilizumab 59 TACI Ig 59 ribavirin RBV 59 liposomal doxorubicin 59 essential thrombocythemia 59 Elagolix 59 paclitaxel Taxol R 59 viral kinetics 59 selective androgen receptor modulator 59 OvaRex ® MAb 59 Ocrelizumab 59 tyrosine kinase inhibitor 59 adult chronic ITP 59 K ras mutations 59 Monotherapy 59 Capecitabine 59 FOLFOX chemotherapy 59 Androxal ® 59 hereditary deficiency 59 Halaven 59 Aloxi injection 59 follicular lymphoma 59 LY# [003] 59 IMC #B 59 situ CIS 59 colorectal cancer liver metastases 59 dexpramipexole 59 tipranavir 59 Phase III Trials 59 Gleevec resistant 59 ASCT 59 Follicular Lymphoma 59 carboplatin 59 Lubiprostone 59 Aurora kinase 59 chemotherapy docetaxel 59 tubulin inhibitor 59 plus gemcitabine 59 Phase Ib 59 refractory gout 59 Phase #b/#a clinical 59 taxane 59 sustained virological response 59 locoregional recurrence 59 TRO# 59 Axitinib 59 T#I mutation 59 BZL# 59 Mitoxantrone 59 external beam radiotherapy 59 odanacatib 59 Pivotal Phase 59 predictive biomarker 59 relapsing remitting multiple sclerosis 59 acute GvHD 59 IIa trial 59 tanespimycin 59 pazopanib 59 ALN PCS 59 bortezomib Velcade R 59 malignant ascites 59 DOXIL 59 nilotinib Tasigna 59 antibody MT# 59 mg/m2 dose 59 DAVANAT 59 evaluating Xcytrin 59 NEUVENGE 59 ASA# 59 sitaxsentan 58 PROVENGE sipuleucel T 58 afatinib 58 Cell Lung Cancer 58 L MTP PE 58 abiraterone 58 FASLODEX 58 dexamethasone Decadron 58 GnRH agonists 58 chemotherapy regimens 58 R roscovitine 58 cyclophosphamide chemotherapy 58 soft tissue sarcomas 58 Rebif ® 58 Omnitarg 58 APOPTONE 58 Thalomid ® 58 Alpharadin 58 CCX# B 58 Alzhemed TM 58 Folfox 58 hA# 58 Apaziquone 58 Solid Tumors 58 vorinostat 58 pancreatic NET 58 Tyrima 58 monoclonal antibody conjugated 58 imatinib resistant 58 recurrent malignant glioma 58 BRIM3 58 Afatinib 58 5 Fluorouracil 58 relapsed CLL 58 3 registrational trial 58 TLK# 58 cisplatin vinorelbine 58 prostate carcinoma 58 ALN TTR 58 Evoltra ® 58 Dacogen decitabine 58 DAPT 58 Exelixis XL# 58 investigational humanized monoclonal antibody 58 taxanes 58 nucleoside analogue 58 prospectively defined 58 trastuzumab DM1 T DM1 58 Enzastaurin 58 invasive aspergillosis 58 PROSTVAC VF 58 CBLC# 58 neratinib 58 Pradefovir 58 ALK inhibitor 58 opioid induced constipation OIC 58 FIRMAGON 58 LHRH antagonist 58 rNAPc2 58 AA amyloidosis 58 phase Ib 58 Diabetic Macular Edema 58 gastrointestinal stromal tumors GIST 58 achieved CCyR 58 taxane refractory 58 dose escalation 58 ocrelizumab 58 lymphadenectomy 58 cytokine refractory 58 Carboplatin 58 eltrombopag 58 FOLFIRI alone 58 AEZS 58 Arimidex anastrozole 58 Onrigin 58 humanized anti 58 ponatinib 58 plus DOXIL 58 AGILECT R 58 CANCIDAS 58 debulking surgery 58 tiuxetan 58 oral picoplatin 58 milatuzumab 58 OvaRex R 58 SCH # 58 EGFR HER2 58 AEGR 58 invasive candidiasis 58 RG# [001] 58 microtubule targeting 58 haematological cancers 58 APPRAISE 58 OZURDEX ® 58 histologies 58 prostate cancer mCRPC 58 Taxotere docetaxel 58 Philadelphia Chromosome Positive 58 chemoresistant 58 XELOX 58 metastatic prostate cancer 58 refractory Hodgkin lymphoma 58 immunomodulatory 58 chronic ITP patients 58 cutaneous T 58 colorectal carcinoma 58 generation purine nucleoside 58 Advaxis Phase 58 Metastatic Melanoma 58 infusional 5-FU/LV 58 Xeloda ® 58 Mimpara 58 completely resected 58 GEM OS1 58 dexanabinol 58 bortezomib Velcade 58 RDEA# 58 acyclovir Lauriad R 58 pediatric acute lymphoblastic 58 virologic response 58 severe hypercholesterolemia 58 dacarbazine chemotherapy 58 Copegus ribavirin 58 MabCampath 58 CALGB # [001] 58 Azacitidine 58 PEGylated Fab fragment 58 orally administered inhibitor 58 CYT# 58 Hycamtin ® 58 KIACTA ™ 58 IV NSCLC 58 Bosutinib 58 chemoradiation 58 Gleevec imatinib mesylate 58 Triapine 58 SABCS 58 neoplasia 58 MyVax R 58 Hodgkin lymphoma NHL 58 Azixa 58 HBeAg positive patients 58 cisplatin gemcitabine 58 trastuzumab Herceptin 58 farletuzumab 58 diagnosed multiple myeloma 58 Stedivaze 58 Cell Lymphoma 58 Nanobody 58 Pralatrexate 58 Bronchitol 58 TKIs 58 metastatic carcinoma 58 FluCAM 58 celgosivir 58 IgG1 monoclonal antibody 58 Free Survival PFS 58 Mantle Cell Lymphoma 58 TO AVOID PREGNANCY WHILE 58 GRN#L 58 PSN# [002] 58 PROSTVAC TM 58 INCB# [002] 58 rapid virologic response 58 bortezomib 58 liposomal formulation 58 idarubicin 58 Raptiva R 58 talabostat 58 JAK1 58 Romiplostim 58 ACAPODENE TM 58 trabedersen 58 YERVOY 58 Actimmune ® 58 HER2 positive cancers 58 Elotuzumab 58 DXL# 58 Sapacitabine 58 nonsmall cell lung cancer 58 EOquin TM 58 Gleevec imatinib 58 retinal vein occlusion 58 Randomized Phase II 58 Phase 1b 58 Phase #b/#a 58 androgen deprivation 58 TASQ 58 anti angiogenic therapy 58 dose cytarabine 58 DCVax ® Brain 58 paclitaxel poliglumex 58 Cannabinor 58 clinical pharmacology studies 58 Campath ® 58 Phenoptin 58 BRIM2 58 CD# CEA 58 dose escalation clinical 58 cisplatin chemotherapy 58 diabetic neuropathic pain 58 advanced epithelial ovarian 58 JAK inhibitors 58 AA Amyloidosis 58 tafamidis 58 anastrozole 58 Panzem R 58 EpCAM 58 Genentech Rituxan 58 taxane therapy 58 vascular disrupting agent 58 RSR# 58 IMiDs ® compound 58 angiogenesis inhibitor 58 BRAF V# mutation 58 HBeAg negative 58 Talabostat 58 Chemophase 58 tumor lysis syndrome 58 IFN α 58 IAP inhibitor 58 INTERCEPT platelets 58 5-FU/LV 58 Enzyme Replacement Therapy 58 antiangiogenic therapy 58 PROMACTA 58 Navelbine ® 58 LHRH agonist 58 CCR9 antagonist 58 Tesetaxel 58 AVONEX ® 58 CINTREDEKIN BESUDOTOX 58 cell chronic lymphocytic 58 indibulin 58 KRAS mutant tumors 58 anti angiogenic agents 58 UPLYSO 58 lenalidomide dexamethasone 58 lapatinib Tykerb 58 acute leukemias 58 Vectibix panitumumab 58 unresectable liver cancer 58 acute myelogenous leukemia AML 58 EGFR tyrosine kinase inhibitor 58 CINQUIL 58 Phase IIb trials 58 Gliadel Wafer 58 LHRH antagonists 58 drug conjugate 58 palifosfamide 58 relapsing multiple sclerosis 58 phase IIb study 58 NXL# 58 Alemtuzumab 58 Vidofludimus 58 overlapping toxicities 58 CML CP 58 cariprazine 58 hepatic metastases 58 ANCHOR trial 58 bazedoxifene 58 ONCONASE 58 cytogenetic responses